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A high proprotion of research relating to cerebral ischemia focuses on neuroprotection. The
application of compounds normally present in the organism is popular, because they do not
greatly influence the  synaptic activity by receptor modulation, and  can  be  administered
without serious side-effects. Oxaloacetate (OxAc) and acetyl-L-carnitine  (ALC) are such
favorable endogenous molecules. ALC can exert a protective effect by improving the energy
state  of the  neurons under ischemic  conditions. A  promising neuroprotective strategy is
glutamate scavenging, which can be achieved by the intravenous administration of OxAc.
This study  involved the possible protective effects of ALC and OxAc in different post-
treatment protocols against long-term potentiation (LTP) impairment. Ischemia was induced
in rats by 2-vessel occlusion, which led to a decreased LTP relative to the control group.
High-dose (200 mg/kg) ALC or OxAc post-treatment resulted in a higher potentiation relative
to the 2VO group, but it did not reach the control level, whereas low-dose ALC (100 mg/kg)
in combination with OxAc completely restored the LTP function. Many previous studies have
concluded that ALC can be protective only as pretreatment. The strategy described here
reveals  that  ALC  can  also  be  neuroprotective  when  utilized  as  post-treatment  against
ischemia.
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Introduction
Stroke is one of the major causes of death: during  the past 20 years the number of stroke
victims has increased by 26-35% (Lozano et al. 2012). The quest for effective neuroprotective
drugs and/or strategies is currently at the focus of much research. Attention recently turned to
compounds normally present in the body, that do not influence synaptic activity by receptor
modulation, and that can be administered in high doses without serious side-effects.
Ischemic conditions are associated with the presence of extremely high levels of glutamate
(Glu) in the brain interstitial fluid (ISF)/cerebrospinal fluid (CSF) (Castillo et al. 1996), which
is one of the major causes of excitotoxicity leading to  cell  death. During physiological
neuronal  activity,  the  Glu  transporters  (present  on  both  nerve  terminals  and  astrocytes)
regulate the extracellular Glu concentration. After release, a high Glu concentration (1 mM)
develops in the synaptic cleft, the transporters then taking up Glu and decreasing its level in
the ISF (around 1 µ M) (Danbolt 2001). On the other hand, the Glu concentration is also
regulated by transporters  located on the antiluminal (brain) side of the blood capillaries
(O'Kane et al. 1999). It was hypothetized  in the early 2000s that a considerable  Glu
concentration gradient between the ISF/CSF and the blood plasma could provide an increased
driving force for the brain-to-blood Glu efflux. This process can be fast and greatly enhanced
by intravenous administration of the blood Glu scavengers oxaloacetate (OxAc) and pyruvate
(Pyr) (Gottlieb et al. 2003). The failure of the cerebral blood flow triggers the activation of the
ischemic cascade. As parts of this process, the failure of ion homeostasis and the increase in
calcium concentration  result in excess activation of the Glu receptors, initiating  Glu
excitotoxicity, which develops immediately after the onset of the ischemic event. While Glu
excitotoxicity takes from minutes up to a few hours, it has the greatest impact on the final
outcome. Excitotoxicity triggers a number of delayed events that further increase the damage
(Dirnagl et al., 1999). The aim of Glu scavenging is to decrease the excess Glu level in the
brain. As a result of this strategy, the i.v. administered scavenger (e.g. OxAc) decreases the
blood Glu level, and the excess Glu can therefore be removed from the brain toward the blood
(Gottlieb et al., 2003). Since excitotoxicity appears in the very initial phase of the ischemic
cascade, Glu scavenging  must be applied as early as possible  after the ischemia. The first
evidence of the neuroprotective effect of Glu scavenging was demonstrated in a closed head
injury model (Zlotnik et al., 2007). Glu scavenging is nowadays an extensively studied feature
of neuroprotective strategies. Its promise is due to the facts that it does not modulate the
receptor functions and it exists physiologically in the human body as an element of the Krebs
cycle, and it can therefore be administered safely.
Another promising  approach to neuroprotection is the administration of different carnitine
derivates. Carnitine (β-hydroxy-γ-N-trimethylaminobutyric acid) can be obtained from meat
and dairy materials, and also by endogenous biosynthesis from L-lysine and L-methionine,
which takes place in the liver and kidney (Borum 1983). The main function of carnitine is to
transport fatty acids across the inner mitochondria  membrane for β-oxidation.  These
compounds  are also scavengers of oxygen free radicals in mammalian tissues (Rani and
Panneerselvam 2002). Acetyl-L-carnitine (ALC), which takes part in the carbohydrate, lipid
and protein metabolism, has the important favorable property of effectively crossing the
blood-brain barrier (Malaguarnera et al. 2011). Glu excitotoxicity is one of the key elements
of the ischemic cascade (Dirnagl et al., 1999), and it has also been demonstrated that ALC can
reduce  the  Glu  outflow  after  focal  cerebral  ischemia  (Jalal  et  al.,  2010).  An  earlier
investigation (Kocsis et al. 2014) revealed that the neuroprotective effect of 100 mg/kg ALC
on global hypoperfusion was observed only in the case of pretreatment, and not after post-
treatment. This is in accordance with the observations of previous in vivo and in vitro studies
(Picconi et al. 2006; Shuaib et al. 1995).
We therefore set out to create a new strategy in which ALC post-treatment can be 
neuroprotective. In the first part of the present study, a higher ALC dose was used than in the 
previously reported experiments (Kocsis et al. 2014). In order to use the lowest concentrations
of the compounds possible, treatment with ALC in combination with OxAc was used in the
second part of the study.
Materials and methods
Animals and housing conditions
Male Wistar  rats  (200-250 g)  supplied by Charles  River  Laboratories were  used in  the
experiments (N=31). The animals were housed individually in standard plastic cages with free
access to food and water. The animal house was light-controled with 12-h/12-h dark/light
cycles and kept under conditions of constant room temperature (23 °C) and humidity. Every
effort was made to minimize the number of animals used and their suffering. The principles of
animal care (NIH publication No. 85-23), and the protocol for animal care approved by both
the Hungarian Health Committee (1998)  and the European Communities Council Directive
(86/609/EEC) were followed. The rats were randomly divided into 5 groups, as follows:
sham-operated controls (N=6); rats subjected to 2-vessel occlusion (2VO) (N=6); 2VO+ALC
post-treatment (N=6); 2VO+OxAc  post-treatment (N=5) and 2VO+OxAc+ALC  post-
treatment (N=8).
Modeling of the hypoperfusion
All surgical procedures were carried out under deep anesthesia. Before the induction  of
transient forebrain ischemia, the rats were anesthetized with sodium pentobarbital (60 mg/ml,
i.p.). Their body temperature was measured continuously  and maintained at 37±0.5 °C by
means of an automatic heat controller (Supertech TMP-5a, Hungary) from the beginning of
the operation until the rats had been awakened. The 2VO method used for the modeling of
transient global hypoperfusion was as described previously (Marosi et al. 2009). The common
carotid arteries were blunt-dissected free by separation from the vagal nerves and connective
tissues, and were clamped with non-traumatic aneurysm clips (Aesculap,  B. Braun Medical
Ltd, Hungary). After a 30-min period of global hypoperfusion, the blood flow in these arteries
was restored by releasing the clips.
Drug administration
The effects of a 100 mg/kg dose of ALC on sham-operated controls, and on 2VO-operated
rats were tested in our previous study  (Kocsis et al. 2014). In the present study, the rats
received 200 mg/kg ALC for 5 additional days after 2VO (once a day). The first treatment
was applied 1 h after the 2VO surgery. ALC was dissolved in 0.9% saline (total volume 1 ml)
and was administered i.p. In the OxAc+ALC-treated group, the OxAc was administered i.v.
(20 mg/100 g/bw) immediately after the reperfusion and the low-dose ALC (100 mg/kg) post-
treatment was then applied for 5 additional days. OxAc was dissolved in distilled water and
the pH was then adjusted to 7.4; the total volume was 1 ml. The effect of OxAc administered
alone was also measured. Figure 1 indicates the time points of the treatments, 2VO surgery
and electrophysiological measurements.
In vitro electrophysiology
The electrophysiological  experiments were conducted 5 days after the ischemic insult. The
animals were killed by decapitation and coronal slices (350 µm) were prepared from the
middle part of the hippocampi with a vibratome (Campden Instruments, UK) in an ice-cold











and 10 D-glucose (all from Sigma, Germany), 




. The slices then were transferred to a Haas recording chamber





(the flow rate of the perfusion was 1.5-2 ml/min). For the electrophysiological
recordings, 1-2  slices  were  used  from  each  animal.  A  bipolar  concentric  stainless  steel
electrode (Neuronelektrod Ltd, Hungary) was placed in the stratum radiatum between the
CA1 and CA2 regions of the hippocampal slices. The stimulus intensity  was adjusted to
between 30 and 70 µ A (constant current, 0.2 ms pulses delivered at 0.05 Hz) to evoke the
half-maximum response. Field excitatory postsynaptic potentials (fEPSPs) were recorded with
a 1.5-2 MΩ resistance glass micropipette filled with aCSF. The recordings were amplified
with a neutralized, high input-impedance preamplifier and filtered (1 Hz-3 kHz). The fEPSPs
were digitized (AIF-03, Experimetria Ltd., Hungary), acquired at a sampling rate of 10 kHz,
saved to a PC and analyzed off-line with Origin Pro 8 software  (OriginLab Corporation,
Northampton, USA). The fEPSPs were monitored for at least 50 min until the amplitudes
were generally stable, and their mean value was determined for the 10-min baseline. For the
induction of long-term potentiation (LTP), theta burst stimulation (TBS) was used (bursts of 4
impulses at 100 Hz, with a train duration of 40 ms and a burst interval of 350 ms). Changes in
fEPSP amplitudes were recorded for a further 60 min.
Statistical analysis
The fEPSP amplitudes were expressed as a percentage of the 10-min baseline value before the
TBS. The Mann-Whitney U-test was chosen for the statistical analysis of the LTP data. Origin
Pro 8 software (OriginLab Corporation, Northampton, USA) was utilized. In each analysis, a
p value of ≤ 0.05 was considered significant.
Results
The effects of ALC and OxAc on the 2VO-induced  LTP impairment were tested on
hippocampal slices. After stabilization of the baseline, a 10-min control period was recorded,
and TBS was then delivered for LTP induction. In the control group, TBS resulted in a
notable fEPSP amplitude increase (145.37±0.25%), which remained stable during the further
60-min. The value of the fEPSP amplitude increasing was 145.79±0.74% at the end of the 
recording period. In the 2VO group, a significantly lower potentiation was observed 
(117.82±0.49%); the amplitudes showed a constant decay over time and had almost reached the
pre-TBS  level  by  the  end  of  the  registrations  (113.10±1.65%).  These  data  are  in 
accordance with our previous findings (Kocsis et al. 2014). Figure 2 shows representative 
fEPSPs from the control and 2VO groups. As a result of the damage caused by the ischemia, 
there were no pathological responses to the stimulation. The recorded neuronal activity was 
normal, and the waveform of the fEPSPs recorded in the 2VO group was the same as that for 
the control group. In the present study, a high-dose ALC (200 mg/kg) was used as post- 
treatment  after  the  transient  global  hypoperfusion.  The  LTP  was  127.05±0.30%  and 
underwent a slight decrease up to the end of the recordings. The level of the potentiation in 
the last 10 min of the registrations was 124.07±1.17%. Even this elevated concentration did 
not restore the LTP function to the control level (similarly to our previous findings with the 
low-dose (100 mg/kg) ALC). When low-dose ALC was applied in combination with OxAc as 
post-treatment, however, the fEPSP amplitude increase returned completely to the control 
level (144.78±0.17%) and it remained stable over time (145.79±0.88%). There was a 
significant difference between the 2VO and OxAc+ALC groups. As a result of the scavenging 
effect of OxAc on the 2VO-induced LTP impairment, the induced LTP was 123.94±0.38%, and 
this potentiation was stable until the end of the recording period (126.03±1.14%) (Fig. 3). The 
result of this treatment was in accordance with our previous findings, since the LTP did not 
regain the control level (unpublished data). OxAc treatment alone partly prevent the decay
of the potentiation relative to the 2VO group, and the fEPSPs stabilized at a lower level, but
did not reach that of the controls.
Discussion
Although cerebral ischemia has remained the leading cause of death in the past 20 years, there
are some drugs which can be used as clinical intervention of ischemic stroke, however one of
the  most  effective  treatment  is  the  thrombolysis. Intensive research  into  neuroprotective
strategies against ischemic injury is therefore ongoing.
One of the most promising methods developed during the last 10 years is Glu scavenging.
This is based on enhancement of the brain-to-blood Glu efflux, which removes the excess Glu
caused by the ischemia/reperfusion injury (Gottlieb et al. 2003). It involves the intravenous
administration of a Glu scavenger, e.g. OxAc or Pyr, as a substrate for a bidirectional process
catalyzed by the blood-resident enzymes Glu-OxAc  transaminase (GOT) or Glu-Pyr
transaminase (GPT), respectively. In the presence of the respective Glu co-substrates, OxAc
or Pyr, GOT or GPT transaminates Glu into 2-α-ketoglutarate  in the blood. This process
reduces the  Glu concentration in  the  blood, resulting in  an  enhanced  Glu concentration
gradient between the brain and the blood, which eliminates the excess Glu from the ischemic
brain (Teichberg et al. 2009). The time-window for the application of Glu scavengers is very
narrow, since Glu excitotoxicity appears immediately after the ischemic insult. This harmful
process can not only  cause damage to the nervous tissue, but also triggers series of other,
delayed events, which worsen  the outcome. These processes  include the peri-infarct
depolarization,  edema, damage to the membranes and the DNA, inflammation and apoptosis
(Dirnagl et al., 1999).
Another direction of the investigations on neuroprotection is the application of compounds
that are physiologically present in the human body; this avoids the harmful side-effects and
difficulties involved in the dosing. One of the most promising  agents is ALC, a naturally
occurring substance that participates in the β-oxidation of fatty acids (Jones et al. 2010).
Pretreatment with 100 mg/kg ALC in our previous study proved to restore the 2VO-impaired
LTP, whereas the post-treatment did not. Our present aim was to find a method in which ALC
can be neuroprotective  as post-treatment, which is of much greater clinical relevance than
pretreatment. We tested the effects of the treatments in one of the most vulnerable regions of
the  brain.  LTP  measurements  were  made  on  hippocampal  slices  in  the  sham-operated
controls, in animals subjected to 2VO, and in 2VO groups post-treated with high-dose ALC
(200 mg/kg), OxAc scavenging  or with the combination of OxAc and low-dose ALC (100
mg/kg). The results in the controls and the 2VO group were similar to our previous findings
(Kocsis et al. 2014). The 30-min global hypoperfusion resulted in an impaired LTP, where the
fEPSP amplitudes were significantly lower relative to those in the control group. In the first
part of the present experiments, we tried to reach a much more noteworthy neuroprotective
effect (relative to our previous study) by only  elevating the concentration of ALC. A 200
mg/kg dose of ALC was slightly more effective than 100 mg/kg (applied previously), but it
did not restore the LTP function to the control level either. It was earlier demonstrated that
particularly pretreatment with ALC can be neuroprotective (Picconi et al. 2006; Shuaib et al.
1995). One possible explanations for the ineffectiveness of ALC post-treatment that is the 
excess Glu appearing immediately after the ischemia results in irreversible, harmful effects 
and leading to cell death (Choi 1988). In our present experiments, Glu scavenging was 
combined with ALC post-treatment. The scavenger OxAc was administered immediately after 
the reperfusion, which caused a decrease in the Glu level in the brain. As a result, ALC post- 
treatment could be much more effective (even in a lower dose). In the OxAc+ALC group, the
combination of the two agents and the two strategies resulted in a completely restored LTP. A
recent review described many  aspects of the protective effect of ALC (Jones et al. 2010).
Among the possible actions of neuroprotection, and one of the main studied mechanisms, is
the stimulation of the aerobic energy metabolism in the brain (Zanelli et al. 2005). After short-
term cerebral ischemia, the extent of glucose oxidation decreases significantly within the first
hour of reperfusion and remains at the reduced level for many hours (Sims 1995). This is most
likely due to the decreased activity of the Pyr dehydrogenase complex (Fukuchi et al. 1998),
which serves as the critical link between the anaerobic and aerobic metabolisms by catalyzing
the oxidative decarboxylation  of Pyr to acetyl CoA (Reed 1981). Under metabolically
compromised circumstances (when the function of the complex is damaged), ALC can serve
as an exogenous, alternative fuel in the presence of a reduced conversion of Pyr to acetyl CoA
(Martin et al. 2005). Furthermore, OxAc (as a member of the Krebs cycle) can also possibly
exert its effect by enhancing the energy metabolism of the cells.
The  present  study  has  revealed  an  approach  for  the  application  of  ALC  in  combined
treatment. This is the first demonstration of the neuroprotective effect of ALC post-treatment
resulting in complete restoration of the LTP function. It is also important that this effect was
achieved through low-dose  ALC post-treatment. Here, we have provided a speculative
explanation which may underly  these results, but the exact mechanisms of the effects of
OxAc+ALC treatment require further investigations.
Acknowledgments
This  work  was  supported  by  grants  from  OTKA  K105077,  Hungarian  Brain  Research 
Program KTIA-13-NAP-A-III/9 and TÁMOP 4.2.2-A-11/KONV-2012-0052. This research 
was  realized  in  the  frames  of  TÁMOP  4.2.4  A/2-11-1-2012-0001 „National  Excellence
Program” – Elaborating and operating  an inland student and researcher personal support
system”. The project was subsidized by the European Union and co-financed by the European
Social Fund.
Conflict of interest
The authors declare that they have no conflict of interest.
Legends to Figures
Fig. 1:
A schematic graph indicating the time  points of the 2VO surgery, the ALC  and OxAc
treatment, and the electrophysiological  experiment. In the case of OxAc treatment, the rats
received the i.v. administration  immediately  after the reperfusion. In the ALC post-treated
groups, the first ALC treatment (i.p.) was applied 1 h after the 2VO surgery, and the animals
received four additional ALC injections.
Fig. 2:
Representative fEPSPs  recorded from the control and the 2VO groups. As a result of the
damage caused by the ischemia there were no pathological responses to the stimulation. The
recorded neuronal activity was normal, and the waveform of the fEPSPs recorded in the 2VO
group was the same as that for the control group.
Fig. 3:
LTP   inducibility   in   the   control,   2VO,   2VO+ALC   post-treatment,   2VO+OxAc   and
2VO+OxAc+ALC post-treatment groups (numbers of electrophysiological recordings: N=11 in
the sham-operated control group, N=10 in the 2VO group, N=9 in the 2VO+ALC post-
treatment group, N=8 in the 2VO+OxAc group and N=10 in the 2VO+OxAc+ALC post-
treatment group). As a result of the ischemia, the potentiation of the fEPSPs was significantly
lower relative to the control level (4). The high-dose ALC post-treatment resulted in a higher
and more stable LTP as compared with the 2VO group (2), but the fEPSP amplitudes did not
reach the control level (1). As a result of the scavenging effect of OxAc, there was a similar
potentiation as that in the high-dose ALC-treated group. The LTP was significantly weaker
than the control (5), but it also was stable relative to the ischemic group and the amplitudes
remained at a constant level during time (6). The increase in the fEPSPs after TBS in the
2VO+OxAc+ALC post-treatment group was  the  same  as  that  in  the  control  group, and
remained stable throughout  the recording period. The LTP of this group was significantly
higher as compared with the 2VO group (3). There was a significant difference between the
2VO+ALC   and   2VO+OxAc+ALC   groups   and   also   between   the   2VO+OxAc   and
2VO+OxAc+ALC  groups.  Furthermore,  there  was  no  sigficant  difference  between  the
2VO+ALC and 2VO+OxAc  groups. Data points are means ± S.E.M. of the normalized
amplitudes of the fEPSPs. Asterisks denote significant differences from the control, and #
denotes significant differences from the data for the 2VO group (**p<0.01, ***p<0.001,
#p<0.05, ###p<0.001; Mann-Whitney U-test).
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